142 related articles for article (PubMed ID: 9697082)
1. A note on sample size determination for bioequivalence studies with high-order crossover designs.
Chen KW; Chow SC; Li G
J Pharmacokinet Biopharm; 1997 Dec; 25(6):753-65. PubMed ID: 9697082
[TBL] [Abstract][Full Text] [Related]
2. On assessment of bioequivalence under a higher-order crossover design.
Chow SC; Liu JP
J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
[TBL] [Abstract][Full Text] [Related]
3. Exact calculation of power and sample size in bioequivalence studies using two one-sided tests.
Shen M; Russek-Cohen E; Slud EV
Pharm Stat; 2015; 14(2):95-101. PubMed ID: 25477145
[TBL] [Abstract][Full Text] [Related]
4. Cost-efficient higher-order crossover designs in comparative bioavailability studies.
Zhou J; Yuan Y; Reynolds R; Raber S; Li Y
Clin Pharmacokinet; 2006; 45(6):623-32. PubMed ID: 16719543
[TBL] [Abstract][Full Text] [Related]
5. On sample size calculation in bioequivalence trials.
Chow SC; Wang H
J Pharmacokinet Pharmacodyn; 2001 Apr; 28(2):155-69. PubMed ID: 11381568
[TBL] [Abstract][Full Text] [Related]
6. Equivalence assessment for interchangeability based on two-sided tests.
Dong X; Tsong Y
J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
[TBL] [Abstract][Full Text] [Related]
7. Sample size determination for equivalence assessment with multiple endpoints.
Sun A; Dong X; Tsong Y
J Biopharm Stat; 2014; 24(6):1203-14. PubMed ID: 25032845
[TBL] [Abstract][Full Text] [Related]
8. Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References.
Song F; Zheng X; Wang Y; Chow SC; Sun H
AAPS J; 2021 Nov; 24(1):3. PubMed ID: 34850298
[TBL] [Abstract][Full Text] [Related]
9. Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs.
Diaz FJ; Berg MJ; Krebill R; Welty T; Gidal BE; Alloway R; Privitera M
Clin Pharmacokinet; 2013 Dec; 52(12):1033-43. PubMed ID: 24085600
[TBL] [Abstract][Full Text] [Related]
10. Sample size calculation for bioequivalence studies with high-order crossover designs.
Qu RP; Zheng H
Control Clin Trials; 2003 Aug; 24(4):436-9. PubMed ID: 12865037
[No Abstract] [Full Text] [Related]
11. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data.
Yu YP; Yan XY; Yao C; Xia JL
Biomed Environ Sci; 2019 Aug; 32(8):614-623. PubMed ID: 31488237
[TBL] [Abstract][Full Text] [Related]
12. Two-stage designs for cross-over bioequivalence trials.
Kieser M; Rauch G
Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
[TBL] [Abstract][Full Text] [Related]
13. A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.
Knahl SIE; Lang B; Fleischer F; Kieser M
Eur J Clin Pharmacol; 2018 May; 74(5):549-559. PubMed ID: 29362819
[TBL] [Abstract][Full Text] [Related]
14. A practical approach for the assessment of bioequivalence under selected higher-order cross-over designs.
Vuorinen J
Stat Med; 1997 Oct; 16(19):2229-43. PubMed ID: 9330430
[TBL] [Abstract][Full Text] [Related]
15. Statistical aspects of bioequivalence testing between two medicinal products.
Zintzaras E
Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):41-6. PubMed ID: 16010860
[TBL] [Abstract][Full Text] [Related]
16. Effect of gastric emptying and entero-hepatic circulation on bioequivalence assessment of ranitidine.
Chrenova J; Durisova M; Mircioiu C; Dedik L
Methods Find Exp Clin Pharmacol; 2010; 32(6):413-9. PubMed ID: 20852750
[TBL] [Abstract][Full Text] [Related]
17. On statistical power for average bioequivalence testing under replicated crossover designs.
Wan H; Chow SC
J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572
[TBL] [Abstract][Full Text] [Related]
18. Influence analysis on crossover design experiment in bioequivalence studies.
Huang Y; Ke BS
Pharm Stat; 2014; 13(2):110-8. PubMed ID: 24338978
[TBL] [Abstract][Full Text] [Related]
19. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
Molins E; Cobo E; Ocaña J
Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence studies: biometrical concepts of alternative designs and pooled analysis.
Zintzaras E; Bouka P
Eur J Drug Metab Pharmacokinet; 1999; 24(3):225-32. PubMed ID: 10716060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
